OrthoPediatrics (NASDAQ:KIDS) Director Sells $234,026.10 in Stock

OrthoPediatrics Corp. (NASDAQ:KIDS) Director David Pelizzon sold 10,131 shares of the company’s stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $23.10, for a total transaction of $234,026.10. Following the completion of the transaction, the director directly owned 6,526,633 shares of the company’s stock, valued at approximately $150,765,222.30. The trade was a 0.15% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

OrthoPediatrics Stock Down 1.3%

Shares of OrthoPediatrics stock traded down $0.31 during trading hours on Tuesday, hitting $23.00. 139,797 shares of the company’s stock traded hands, compared to its average volume of 173,766. OrthoPediatrics Corp. has a twelve month low of $14.42 and a twelve month high of $26.74. The company has a market cap of $600.53 million, a PE ratio of -13.69 and a beta of 0.98. The company has a quick ratio of 2.17, a current ratio of 4.78 and a debt-to-equity ratio of 0.28. The stock has a 50 day simple moving average of $21.52 and a 200-day simple moving average of $18.72.

OrthoPediatrics (NASDAQ:KIDS) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.04. The business had revenue of $70.51 million for the quarter, compared to analysts’ expectations of $68.21 million. OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 15.72%. Equities research analysts anticipate that OrthoPediatrics Corp. will post -1.14 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. BTIG Research upped their target price on OrthoPediatrics from $24.00 to $29.00 and gave the company a “buy” rating in a research report on Thursday, August 20th. Needham & Company LLC raised their price target on shares of OrthoPediatrics from $30.00 to $35.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Weiss Ratings upgraded shares of OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, August 5th. Piper Sandler reaffirmed an “overweight” rating and issued a $25.00 price target (up from $22.00) on shares of OrthoPediatrics in a report on Wednesday, August 5th. Finally, TD Cowen reaffirmed a “buy” rating on shares of OrthoPediatrics in a report on Monday, June 15th. Nine equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $26.44.

Hedge Funds Weigh In On OrthoPediatrics

A number of hedge funds have recently bought and sold shares of the company. Russell Investments Group Ltd. increased its holdings in OrthoPediatrics by 433.1% in the third quarter. Russell Investments Group Ltd. now owns 1,402 shares of the company’s stock valued at $26,000 after buying an additional 1,139 shares during the last quarter. Legal & General Group Plc acquired a new stake in OrthoPediatrics during the second quarter valued at approximately $34,000. Northwestern Mutual Wealth Management Co. lifted its holdings in OrthoPediatrics by 5,226.5% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,610 shares of the company’s stock worth $46,000 after buying an additional 2,561 shares during the last quarter. Caption Management LLC bought a new position in OrthoPediatrics during the 3rd quarter worth approximately $54,000. Finally, BNP Paribas Financial Markets grew its position in shares of OrthoPediatrics by 60.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 3,288 shares of the company’s stock worth $61,000 after acquiring an additional 1,235 shares in the last quarter. 69.05% of the stock is currently owned by institutional investors and hedge funds.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.